This talk will discuss the options of STI prevention in the context of pre-exposure prophylaxis (PrEP) for HIV prevention. With the expansion of both HIV PrEP and anti-viral treatment for HIV over the last decade there has co incidentally been a global surge in incident STI infections notably with the most evaluated being infections caused by Neisseria Gonorrhea (GC), Chlamydia Trachomatis (CT) and Treponema Pallidum (Syphilis). Over 1 million curable STI’s are diagnosed daily globally. This has been both among both the general population, and more marked among key populations. The knowledge of undetectable equals untransmittable (U=U and there has not been directly linked to this observation. Notably, there has also not been a reduction in the reporting of condomless sex. HIV PrEP has had a remarkably expansion especially in SSA, but there are challenges of high initiation, but adherence and persistence being inconsistent. STI antimicrobial prophylaxis has been explored in several studies and concerns are still raised around possible resistance to current antimicrobial agents as has been noted particularly with GC. The presentation will explore the options of prophylaxis of STI’s management s and also suggest mechanisms for programmatic and research implications by drawing on research done globally with a focus on doxycycline for STI prophylaxis.